News
Fri, 30 Oct 2020 05:42:00 -0400
Fri, 30 Oct 2020 05:42:00 -0400
Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020
PROFIT AND LOSS |
9M 2020 |
9M 2019 |
Growth |
Growth |
USD million |
|
|
|
|
Net sales |
14,274 |
13,488 |
6% |
7% |
Operating profit |
6,466 |
6,113 |
6% |
7% |
|
|
|
|
|
Net profit |
4,941 |
4,551 |
9% |
N/A |
Diluted earnings per share (in USD) |
2.11 |
1.91 |
10% |
N/A |
* CER: Constant exchange rates (average 2019). The growth at CER was announced on 8 October
**For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.64191
Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the performance in the first nine months of 2020 despite the negative impacts from COVID-19. More patients use our GLP-1 treatments, and our diabetes market leadership continues to expand. Within R&D, an important milestone was reached with the encouraging results from the phase 2b trial in cardiovascular disease with ziltivekimab, the lead candidate from Corvidia Therapeutics that was acquired this year".
On 30 October 2020 at 13.00 CET, corresponding to 8.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.